特发性肺纤维化的分子内型:两项多中心观察队列的潜在类别分析
类别2生物标志物浓度更高且死亡或移植风险更高,并在汇总分析中对抗纤维化治疗显示有利反应,类别1则无。
要点
- IPF可基于血浆生物标志物分为两种分子内型,WFDC2是类别归属的最重要决定因素。
- 类别2死亡或移植风险显著高于类别1,发现队列HR 2.02,验证队列HR 1.95。
- 类别2对抗纤维化治疗有有利反应(HR 0.64),类别1无显著反应,内型间交互P=0.030。
核心结论
- 在两项多中心观察队列中识别出两种IPF分子内型,其临床结局和对未来抗纤维化治疗的反应存在差异。
- 这些内型有待进一步验证,可能为未来IPF临床试验提供精准医学方法。
研究设计与样本
- 研究在前瞻性招募的发现队列(n=875)和验证队列(n=347)中独立进行潜在类别分析(LCA)。
- 采用多因素Cox回归调整基线混杂因素,检验分子内型与4年无移植生存的关联。
- 在生物标志物测量时未接受抗纤维化治疗的患者汇总队列(n=555)中评估内型依赖的差异化治疗反应。
主要发现
- 两个队列中LCA均独立识别出两个潜在类别(P < 0.0001)。
- WFDC2(WAP四二硫化物核心域蛋白2)是跨队列类别归属的最重要决定因素。
- 类别2特征为生物标志物浓度更高且死亡或移植风险更高:发现队列HR 2.02(95%CI 1.64-2.48;P < 0.001),验证队列HR 1.95(95%CI 1.34-2.82;P < 0.001)。
- 汇总分析中内型间治疗效应存在显著异质性(交互P = 0.030),类别2抗纤维化反应有利(HR 0.64;95%CI 0.45-0.93;P = 0.018),类别1无显著反应(HR 1.19;95%CI 0.77-1.84;P = 0.422)。
临床怎么用
- 基于血浆生物标志物(尤其WFDC2)的分子内型分型可能有助于识别更可能从抗纤维化治疗中获益的IPF患者。
- 该分型策略尚需进一步验证,暂不宜直接用于临床治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Idiopathic pulmonary fibrosis (IPF) causes irreversible fibrosis of the lung parenchyma. Although antifibrotic therapy can slow IPF progression, treatment response is variable. There exists a critical need to develop a precision medicine approach to IPF. Objectives: To identify and validate biologically driven molecular endotypes of IPF. Methods: Latent class analysis (LCA) was independently performed in prospectively recruited discovery (n = 875) and validation (n = 347) cohorts. Twenty-five plasma biomarkers associated with fibrogenesis served as class-defining variables. The association between molecular endotype and 4-year transplant-free survival was tested using multivariable Cox regression adjusted for baseline confounders. Endotype-dependent differential treatment response to future antifibrotic exposure was then assessed in a pooled cohort of patients naive to antifibrotic therapy at the time of biomarker measurement (n = 555). Measurements and Main Results: LCA independently identified two latent classes in both cohorts (P < 0.0001). WFDC2 (WAP four-disulfide core domain protein 2) was the most important determinant of class membership across cohorts. Membership in class 2 was characterized by higher biomarker concentrations and a higher risk of death or transplant (discovery, hazard ratio [HR], 2.02; 95% confidence interval [CI], 1.64-2.48; P < 0.001; validation, HR, 1.95; 95% CI, 1.34-2.82; P < 0.001). In pooled analysis, significant heterogeneity in treatment effect was observed between endotypes (P = 0.030 for interaction), with a favorable antifibrotic response in class 2 (HR, 0.64; 95% CI, 0.45-0.93; P = 0.018) but not in class 1 (HR, 1.19; 95% CI, 0.77-1.84; P = 0.422). Conclusions: In this multicohort study, we identified two novel molecular endotypes of IPF with divergent clinical outcomes and responses to antifibrotic therapy. Pending further validation, these endotypes could enable a precision medicine approach for future IPF clinical trials.
引用
- Maddali MV, Moore AR, Sinha P, et al. Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts. Am J Respir Crit Care Med. 2024. PMID: 38913573. doi:10.1164/rccm.202402-0339OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。